Asclepios S.A.

Wholesale of pharmaceutical goods

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2002-02-28
Share capital
9,450,000.00 PLN
Activity description

Asclepios S.A. operates a pharmaceutical wholesaler with warehouse facilities. Its activities include sales and telemarketing, nutrition, contract fulfillment and tenders; its DPD certificate has been confirmed by the GIF.

Registered address
Hubska 44, 50-502 Wrocław, Poland
Opening hours
Mon–Fri, 8:00–16:00
Email
Phone
Electronic delivery address
AE:PL-87959-66556-UDUVA-19

Financials

Revenue history (in m)

From the notes

Current income tax (CIT due)$1,996,187

Filing timeliness

Financial statements were filed on time, on average 53 days early. All were audited by a statutory auditor.

  • 202510/06/2026
  • 202406/06/2025
  • 202317/05/2024
  • 202222/06/2023
  • 202104/07/2022
  • 202019/05/2021
Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.

Industry · Wholesale of pharmaceutical goods23 / 1,137
Top 2.0%
Division · Wholesale trade101 / 20,054
Top <1%
City · Wrocław23 / 13,656
Top <1%
Voivodeship · Dolnośląskie55 / 23,844
Top <1%
Country · Poland742 / 297,266
Top <1%

Results vs industry

Revenue
This companyUSD 291.17mMedianUSD 1.08mAverageUSD 22.53m
Net profit
This companyUSD 8.38mMedianUSD 38.88kAverageUSD 884.46k
Operating costs
This companyUSD 274.55mMedianUSD 962.19kAverageUSD 21.20m
Assets
This companyUSD 87.78mMedianUSD 609.97kAverageUSD 11.91m

Offer

  • Medicines
  • Imported medicines
  • Antibiotics
  • Cytostatic medicines
  • Pharmaceutical logistics

Websites

The sites are available in: Polish and English.

Public procurement

3648 tenders recorded as contractor: 1142 national ($43,055,493) and 2506 EU ($1,090,078,679).

SubjectAmount
Supply of medicines
$768.5K
Supply of medicines, lot 2
$36,131
Supply of medicines, lot 2
$44,666

Authorized Representatives

Tomasz Arkadiusz Jóźwik age 61 – President of the Management Board
Artur Rzegocki age 55 – Vice President of the Management Board
Bartłomiej Jan Sawicki age 50 – Attorney-in-fact (sole)

Manner of representation

The following are authorized to represent the company and act on its behalf: 1. the President of the Management Board independently; 2. two members of the management board or one member of the management board jointly with a commercial proxy; 3. an independent commercial proxy independently.

Supervisory board

Paweł Andrzej Szewczyk age 56 – Supervisory Board Member
Krzysztof Bernard Wojtas age 70 – Supervisory Board Member
Wiesław Bociek age 71 – Supervisory Board Member

Beneficial owners

Person

Subsidiaries

NameStake
15%

Bank accounts

Registered as a VAT taxpayer on 1995-08-03.

Debt

No entries in the National Debtors Register (KRZ).

Real estate

TypeAmount
Buildings and premises
PLN 22,411

MSiG notices

Publication dateEvent
Dec 7, 2020Commercial Companies Code notice
Nov 20, 2020Commercial Companies Code notice
Nov 5, 2020Commercial Companies Code notice
Oct 21, 2020Commercial Companies Code notice

Public aid

11 public aid cases recorded, with a total value of $1,929,397.

PurposeGross amount
Liquidity support for undertakings affected by the war in Ukraine
$398.7K
Liquidity support for undertakings affected by the war in Ukraine
$144.6K
Liquidity support for undertakings affected by the war in Ukraine
$65,537

Regulatory authorisations

AuthorityTypeStatus
BDO register entry Active

Competitors

Name
Przedsiębiorstwo Dystrybucji Farmaceutycznej Slawex sp. z o.o.
Salus International sp. z o.o.
Hurtap S.A.
Medi&More sp. z o.o.
Abbvie sp. z o.o.
Novo S.A.
Medivet S.A.
Tramco sp. z o.o.
Lubfarm S.A.
Przedsiębiorstwo Zaopatrzenia Farmaceutycznego Cefarm-Warszawa S.A.

Change history

DateEvent
2021-06-18Share capital increase
2018-03-28Share capital increase
2016-03-31Share capital increase
2012-06-28Share capital increase
2011-08-16Share capital increase

FAQ

Last updated: 2026-06-22